T2D, Obesity and Heart Failure: Breaking the Pathophysiologic Triangle

India's diabetes burden has risen markedly, with 101 million individuals living with diabetes¹. The clinical burden is compounded by heart failure (HF), affecting nearly 50% of individuals with T2D in India. The interplay of multiple modifiable comorbidities, including obesity, CAD, hypertension, etc., further amplifies the complexity of managing HF in T2DM patients².

T2D & HF Risk: Obesity Intensifying Heart Failure

T2DM patients carry a 2–5 times higher cardiovascular risk, with more than 50% of deaths attributable to CVD. Progressive HbA1c increases are accompanied by increases in HF risk — yet BMI outperforms HbA1c in predicting HF episodes. Each 1 kg/m² BMI increase raises HF risk by 5–7%, while each 5-unit BMI increase is associated with a 41% higher HF risk. Interestingly, in the absence of adiposity, diabetes alone was not consistently associated with HFpEF — confirming obesity as the dominant driver of HF risk in T2DM, with obese T2D-HFpEF patients facing greater exercise intolerance, more HF hospitalisations, and worse prognosis^3,4.

Heart Failure Drivers in Obese T2D: Hyperglycemia & Adiposity Dynamics

T2D promotes heart failure through two divergent pathways. Hyperglycemia drives maladaptive signaling via the hexosamine, polyol, and pentose phosphate pathways, alongside advanced glycation end products. More critically, visceral adiposity causes adipokine imbalance, cardiac steatosis, and pericardial constraint — emerging as the predominant mechanistic driver of diabetes-associated HF. (Figure 1)4

Figure 1: Visceral Adiposity & Hyperglycemia: Interactions Driving Development and Progression of Heart Failure

Impact of Weight Reduction on HF Incidence in Obese T2D

Evidence from the Look AHEAD trial sub-analysis demonstrated that a 10% BMI decrease over 1-year and 4-year periods was independently associated with 31% and 20% reductions in incident heart failure (HF), respectively, among overweight/obese adults with T2DM⁵. Similarly, in the SELECT trial, subcutaneous semaglutide injections-mediated 8.5% weight loss yielded an 18% reduction in the HF composite endpoint (HR: 0.82; 95% CI: 0.71–0.96)⁶ . Retrospective bariatric surgery data further support these findings, with Roux-en-Y gastric bypass achieving a 62% reduction in incident HF (HR: 0.38; 95% CI: 0.22–0.64) following a mean 30% BMI decrease at 5 years ⁷.

Targeting Weight Reduction to Improve Heart Failure Outcomes in T2D – Scientific Societies’ Recommendations

The ICMR Standard Treatment Workflow (STW) for Heart Failure (January 2026) favored and suggested weight reduction at all levels of care settings (across PHC, CHC, district hospital, and tertiary care settings) in HF patients⁸. Aligning with this, the Consensus Statement from the Heart Failure Society of America (HFSA) Scientific Statements Committee also recommends at least 5%–10% weight loss for patients with heart failure and BMI ≥35 kg/m2⁹.

The Heart Failure Association of India (HFAI) guidelines for Diagnosis and Management of Heart Failure (2025) also recommended that weight reduction strategies should be advised to HF patients. Further, the guideline cited that semaglutide, which reduced obesity in the SELECT trial, also reduced heart failure hospitalizations¹⁰.

The ACC in their 2025 Scientific Statement on "Management of Obesity in Adults with Heart Failure" noted that among GLP-1 receptor agonists, injectable semaglutide has shown improvements in symptoms, functional capacity, quality of life, and weight reduction in patients with HFpEF and obesity, based on trials enrolling individuals with BMI ≥30 kg/m²¹¹.

NICE NG28 (February 2026) also recommends subcutaneous semaglutide as first-line triple therapy alongside metformin and an SGLT2 inhibitor in T2D patients with established atherosclerotic cardiovascular disease¹².

Reimagining the Future of T2D Patient Care: Broader integration of GLP-1 RA

As access to GLP-1 RAs grows in India, injectable semaglutide is expected to significantly advance the management of patients with T2D and heart failure.

Beyond glycaemic control, subcutaneous semaglutide reduces CV death, HF and non-fatal MI by 20% (SELECT; HR 0.80), lowers NT-proBNP levels, and delivers sustained weight reduction — collectively addressing the obesity–inflammation–cardiac remodeling axis – the pathophysiologic triangle driving HF progression in T2DM.

Final Words

● India's 101 million T2DM patients face a compounding HF burden; affecting nearly 50% of individuals with T2D — with obesity emerging as the dominant driver.

● Visceral adiposity drives HF through adipokine imbalance, cardiac steatosis, and pericardial constraint — with hyperglycaemia further amplifying maladaptive cardiac signaling via advanced glycation end products and hexosamine pathway activation.

● Evidence confirms a proportional cardiometabolic benefit — 10% BMI reduction reducing incident HF by 31%, semaglutide-mediated 8.5% weight loss yielding 18% reduction in HF composite endpoint, and bariatric surgery achieving 62% reduction in incident HF.

● ICMR STW 2026, HFSA, HFAI 2025, and ACC 2025 suggest weight-targeted therapy among cornerstone interventions for HF management in obese T2DM patients.

● As GLP-1 RA access broadens in India, injectable semaglutide-based treatment will herald a transformative era in T2D-HF management.

Abbreviations: ACC, American College of Cardiology; AGE, advanced glycation end products; BMI, body mass index; CAD, coronary artery disease; CHC, community health centre; CI, confidence interval; CVD, cardiovascular disease; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; HF, heart failure; HFAI, Heart Failure Association of India; HFSA, Heart Failure Society of America; HFpEF, heart failure with preserved ejection fraction; HR, hazard ratio; ICMR, Indian Council of Medical Research; MI, myocardial infarction; NICE NG28, National Institute for Health and Care Excellence Guideline 28; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PHC, primary health centre; RYGB, Roux-en-Y gastric bypass; SGLT2i, sodium-glucose cotransporter-2 inhibitor; STW, Standard Treatment Workflow; T2D/T2DM, type 2 diabetes mellitus; HFAI guidelines – Heart Failure Association of India